In vitro metabolism of eupatilin by multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes

Xenobiotica

Volumn 37, Issue 8, 2007, Pages 803-817

  Lee, H S ^a   Ji, H Y ^a   Park, E J ^a   Kim, S Y ^a  

^a Wonkwang University   (South Korea)

Author keywords

CYP1A2; CYP2C8; Eupatilin metabolism; O demethylation; UGT1A1; UGT1A10; UGT1A3; UGT1A7; UGT1A8; UGT1A9

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; EUPATILIN; FLAVONE DERIVATIVE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PROTEIN FUNCTION;

ANTIBODIES; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; FLAVONOIDS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MICROSOMES, LIVER;

ARTEMISIA;

EID: 34547946590     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701534877     Document Type: Article

References (29)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 25:261-270.
2. Cheng Z, Radominska-Pandya A, Tephly TR. 1998. Cloning and expression of human UDP-glucuronosyltransferse (UGT) 1A8. Archives of Biochemistry and Biophysics 356:301-305.
3. Galijatovic A, Otake Y, Walle UK, Walle T. 2001. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells-potential role in Caco-2 cells-potential role in carcinogen bioinactivation. Pharmaceutical Research 18:374-379.
4. Guillemette C. 2003. Pharmacogenomics of human UDP- glucuronosyltransferase enzymes. Pharmacogenomics Journal 3:136-158.
5. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ. 1999. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clinical Pharmacology and Therapeutics 65:576-582.
6. Jang JM, Park KJ, Kim DG, Shim HJ, Ahn BO, Kim SH, Kim WB. 2003. Pharmacokinetics of a new antigastric agent, eupatilin, an active component of Stillen®, in rats. Journal of Applied Pharmacology 11:163-168.
7. Ji HY, Lee HW, Shim HJ, Kim SH, Kim WB, Lee HS. 2004. Metabolism of eupatilin in rats using liquid chromatography/electrospray mass spectrometry. Biomedical Chromatography 18:173-177.
8. Kiang TKL, Ensom MHH, Chang TKH. 2005. UDP-glucuronosyltransferses and clinical drug-drug interactions. Pharmacology and Therapeutics 106:97-132.
9. Kim AR, Zou YN, Park TH, Shim KH, Kim MS, Kim ND, Kim JD, Bae SJ, Choi JS, Chung HY. 2004. Active components from Artemisia iwayomogi displaying ONOO(-) scavenging activity. Phytotherapy Research 18:1-7.
10. Kim MJ, Kim DH, Na HK, Oh TY, Shin CY, Surh YJ. 2005a. Eupatilin a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human gastric cancer (AGS) cells. Journal of Environmental Pathology and Toxicological Oncology 24:261-269.
11. Kim JY, Kwon EY, Lee YS, Kim WB, Ro JY. 2005b. Eupatilin blocks mediator release via tyrosine kinase inhibition in activated guinea pig lung mast cells. Journal of Toxicology and Environmental Health Part A 68:2063-2080.
12. Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T. 1983. Selective inhibition of 5-lipoxygenase by natural compounds isolated from Chinese plants. Artemiae rubripes Nakai. FEBS Letters 1158:41-44.
13. Miners JO, McKinnon RA. 2000. CYP1A. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia, PA: Lippincott Williams & Wilkins. pp 61-73.
14. Miners JO, Knight KM, Houston JB, Mackenzie PI. 2006. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochemical Pharmacology 71:1531-1539.
15. Naganuma M, Saruwatari A, Okamura S, Tamura H. 2006. Turmeric and curcumin modulate the conjugation of 1-naphtol in Caco-2 cells. Biological and Pharmaceutical Bulletin 29:1476-1479.
16. Newton DJ, Wang RW, Lu AY. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 23:154-158.
17. Park SC, Yoon JH, Kim W, Gwak G-Y, Kim KM, Lee SH, Lee S-M, Lee H-S. 2006. Eupatilin attenuates bile acid-induced hepatocyte apoptosis. Journal of Gastroenterology 41:772-778.
18. Rae JM, Soukhova NV, Flockhart DA, Desta Z. 2002. Triethylenethiophosphamide is a specific inhibitor of cytochrome P-450 2B6: Implications for cyclophosphamide metabolism. Drug Metabolism and Disposition 30:520-530.
19. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. 1993. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239-249.
20. Seo HJ, Surh YJ. 2001. Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human promyelocytic leukemia cells. Mutation Research 496:191-198.
21. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De la Torre R, Davies DS. 1990. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 29:651-663.
22. Shimada T, Yamazaki H, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
23. Shipkova M, Wieland E. 2005. Glucuronidation in therapeutic drug monitoring. Clinica Chimica Acta 358:2-23.
24. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. 1997. Differential expression of the UGT1A locus in human liver, biliary and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissues. Molecular Pharmacology 52:212-220.
25. Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. 2002. (+)-N-3-benzyl-nirvanol and (-)-N-3-benzylphenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 30:235-239.
26. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 1998. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. Journal of Pharmaceutical Science 87:845-853.
27. Walsky RL, Obach RS, Gaman EA, Gleeson JPR, Proctor WR. 2005. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metabolism and Disposition 33:413-418.
28. Yun CH, Shimada T, Guengerich FP. 1991, Purification and characterization of human liver microsomal cytochrome P450 2A6. Molecular Pharmacology 40:679-685.
29. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. 2005. In vitro inhibition of UDP-glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metabolism and Disposition 33:1729-1739.